A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02963831 |
|
Recruitment Status :
Recruiting
First Posted : November 15, 2016
Last Update Posted : February 23, 2021
|
Sponsor:
Ludwig Institute for Cancer Research
Collaborators:
Cancer Research Institute, New York City
MedImmune LLC
Targovax ASA
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2021 |
| Estimated Study Completion Date : | December 2022 |